The funds raised will enable CoreMap to develop more precise data-driven tools to address atrial fibrillation ablation.
CoreMap, a US-based medtech, has announced the closure of an oversubscribed Series C funding round, which was led by Medtronic and included participation from existing and new investors.
The organisation, which was established in 2016 and is headquartered in Burlington, Massachusetts, focuses on advancing the diagnosis and treatment of atrial fibrillation. This is a common heart rhythm disorder in which the beat is irregular.
CoreMap will put some of the funds raised towards further developing its electrophysiology mapping system, which is designed to provide physicians with atrial fibrillation (AF) ablation guidance, based on large data sets of highly accurate electrical activation data.
Ablation is a technique that targets tissue in the heart, creating tiny scars via radiofrequency or pulsed field energy; this works to block the faulty signals that result in the irregular heartbeat.
